Table 1.
Demographic, clinical and pathological characteristics of the CIS (curative intent surgery) and PAT (palliative therapy) subgroup during the three study periods.
| Variable | Curative Group (CIS) | Palliative Group (PAT) | ||||||
|---|---|---|---|---|---|---|---|---|
| 2003–2006 n = 42 | 2007–2010 n = 56 | 2011–2014 n = 72 | p * | 2003–2006 n = 104 | 2007–2010 n = 86 | 2011–2014 n = 60 | p * | |
| Age at mCRC dx: Mean (SD) | 66.0 (9.8) | 65.0 (10.6) | 63.7 (10.7) | 0.507 † | 67.0 (11.5) | 70.2 (11.6) | 74.0 (11.2) | 0.001 † |
| BMI: Mean (SD) | 25.9 (4.1) | 24.9 (3.5) | 25.2 (4.5) | 0.487 † | 25.3 (4.2) | 25.9 (4.7) | 24.7 (4.7) | 0.276 † |
| Sex: Male | 32 (76%) | 32 (57%) | 44 (61%) | 0.130 | 68 (65%) | 52 (61%) | 34 (57%) | 0.524 |
| ASA | 0.519 | 0.144 | ||||||
| I | 3 (7%) | 7 (13%) | 5 (7%) | 10 (10%) | 8 (9%) | 1 (2%) | ||
| II | 25 (60%) | 34 (61%) | 47 (65%) | 46 (45%) | 31 (36%) | 23 (38%) | ||
| III | 14 (33%) | 13 (23%) | 20 (28%) | 38 (37%) | 42 (49%) | 27 (45%) | ||
| IV/V | 0 (0%) | 2 (4%) | 0 (0%) | 9 (9%) | 5 (6%) | 9 (15%) | ||
| Primary TU Location | 0.821 | 0.085 | ||||||
| Colon | 22 (52%) | 30 (54%) | 37 (51%) | 64 (62%) | 59 (69%) | 47 (78%) | ||
| Rectum | 19 (45%) | 26 (46%) | 33 (49%) | 40 (39%) | 25 (29%) | 12 (20%) | ||
| Both | 1 (2%) | 0 (0%) | 2 (3%) | 0 (0%) | 2 (2%) | 1 (0%) | ||
| Primary TU UICC Stage | 0.116 | 0.885 | ||||||
| I | 2 (5%) | 3 (5%) | 4 (6%) | 4 (4%) | 2 (2%) | 2 (3%) | ||
| II | 5 (12%) | 8 (14%) | 4 (6%) | 9 (9%) | 5 (6%) | 5 (8%) | ||
| III | 19 (45%) | 12 (21%) | 20 (28%) | 23 (22%) | 17 (20%) | 9 (15%) | ||
| IV | 16 (38%) | 33 (59%) | 44 (61%) | 68 (65%) | 62 (72%) | 44 (73%) | ||
| Timing of mCRC: synchronous | 18 (43%) | 35 (63%) | 45 (63%) | 0.082 | 75 (72%) | 61 (71%) | 46 (77%) | 0.730 |
| CEA at stage IV: Mean—ng/mL (SD) | 128.4 (680) | 116.3 (398) | 98.0 (331) | 0.946 † | 335.4 (988) | 276.3 (714) | 461.0 (1404) | 0.585 † |
| Initial metastatic site | ||||||||
| Hepatic | 31 (74%) | 40 (71%) | 46 (64%) | 0.477 | 77 (74%) | 64 (74%) | 50 (83%) | 0.348 |
| Pulmonary | 9 (21%) | 20 (36%) | 23 (32%) | 0.299 | 26 (25%) | 27 (31%) | 27 (45%) | 0.030 |
| Hepatic + Pulmonary | 1 (2%) | 4 (7%) | 5 (7%) | 0.650 | 18 (17%) | 18 (21%) | 21 (36%) | 0.025 |
| Peritoneal | 0 (0%) | 2 (4%) | 10 (14%) | 0.009 | 29 (28%) | 26 (30%) | 17 (28%) | 0.935 |
| Distant lymph nodes | 4 (10%) | 2 (4%) | 3 (4%) | 0.461 | 15 (14%) | 10 (12%) | 3 (5%) | 0.173 |
| Others | 1 (2%) | 2 (4%) | 5 (7%) | 0.593 | 13 (13%) | 10 (12%) | 8 (13%) | 0.969 |
* χ² or Fisher’s exact test, except †: ANOVA. ASA: American Society of Anaesthesiologists; BMI: Body mass index; CEA: carcinoembryogenic antigen; dx: diagnosis; mCRC: metastatic colorectal cancer; SD: standard deviation; TU: tumour; UICC: Union internationale contre le cancer.